Formulation Selection and Subsequent Optimization of Two Different Oral Formulations of BI 894416 in Healthy Male Subjects (Open-label, Randomised, Single-dose Study in Two Parts; Trial Part 1: Five-period Crossover Design With an Additional Sixth Period in a Fixed Sequence; Trial Part 2: Three-period Crossover Followed by a Two-period Crossover Design)
Latest Information Update: 25 Sep 2024
At a glance
Most Recent Events
- 02 Nov 2021 Status changed from completed to discontinued due to company decision.
- 10 Jan 2021 Status changed from recruiting to completed.
- 16 Nov 2020 Planned End Date changed from 24 Dec 2020 to 10 Mar 2021.